Intas Pharmaceuticals Limited undertook a big step which will bring relief to a large number of cancer patients in the country for whom the drug Bevacizumab was out of reach till today. Intas's Bevacizumab therapy is priced at 39,995 for the dose strength of the 400 mg variant which makes it 60 percent less than the currently available options.

Bevacizumab is a drug that works by slowing the growth of new blood vessels and is used in treating multiple-cancers like colorectal cancer, ovarian cancer, cervical cancer, lung cancer, and recurrent glioblastoma (a type of brain tumor). The drug has been available in India since 2004 but the cost has been so prohibitive that as per eminent clinicians of the country they have been able to give this drug to very few eligible patients.

Every year over seven lakh patients die due to various types of cancer in India. In order to relieve the patients from the financial burden associated with the treatment, the organization implemented this cost-effective measure. The step is entirely focused in making the drug treatment accessible to cancer patients in India thus, providing them with a beacon of hope in their fight against the disease.


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version